The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents
Open accessAbstract
OBJECTIVES: To assess the clinical and cost-effectiveness of oral methylphenidate hydrochloride (MPH), dexamfetaminesulphate (DEX) and atomoxetine (ATX) in children and adolescents (<18 years of age) diagnosed with attention deficit hyperactivity disorder (ADHD) (including hyperkinetic disorder). DATA SOURCES: Electronic databases covering 1999--July 2004 for MPH, 1997--July 2004 for DEX and 1981--July 2004 for ATX. REVIEW METHODS: Selected studies were assessed using modified criteria based on CRD Report No. 4. Clinical effectiveness data were reported separately for each drug and by the type of comparison. Data for MPH were also analysed separately based on whether it was administered as an immediate release (IR) or extended release (ER) formulation. For all drugs, the data were examined by dose. Data for the core outcomes of hyperactivity (using any scale), Clinical Global Impression [as a proxy of quality of life (QoL)] and adverse events were reported. For crossover studies, the mean and standard deviation (SD) for each outcome were data extracted for end of trial data (i.e. baseline data were not considered). For parallel studies, change scores were reported where given, otherwise means and SDs were presented for end of trial data. In addition, mean differences with 95% confidence intervals were calculated for each study. For adverse events, self-ratings were reported when used, otherwise, parent reports were utilised. Percentages of participants reporting adverse events were used to calculate numbers of events in each treatment arm. All the clinical effectiveness data and economic evaluations (including accompanying models) included in the company submissions were assessed. A new model was developed to assess the cost-effectiveness of the alternative treatments in terms of cost per quality-adjusted life-year. To achieve this, a mixed treatment comparison model was used to estimate the differential mean response rates. Monte Carlo simulation was used to reflect uncertainty in the cost-effectiveness results. RESULTS: In total, 65 papers met the inclusion criteria. The results suggest that MPH and DEX are effective at reducing hyperactivity and improving QoL (as determined by Clinical Global Impression) in children, although the reliability of the MPH study results is not known and there were only a small number of DEX studies. There was consistent evidence that ATX was superior to placebo for hyperactivity and Clinical Global Impression. Studies on ATX more often reported the study methodology well, and the results were likely to be reliable. Very few studies made direct head-to-head comparisons between the drugs or examined a non-drug intervention in combination with MPH, DEX or ATX. Adequate and informative data regarding the potential adverse effects of the drugs were also lacking. The results of the economic evaluation clearly identified an optimal treatment strategy of DEX first-line, followed by IR-MPH for treatment failures, followed by ATX for repeat treatment failures. Where DEX is unsuitable as a first-line therapy, the optimal strategy is IR-MPH first-line, followed by DEX and then ATX. For patients contraindicated to stimulants, ATX is preferred to no treatment. For patients in whom a midday dose of medication is unworkable, ER-MPH is preferred to ATX, and ER-MPH12 appears more cost-effective than ER-MPH8. As identified in the clinical effectiveness review, the reporting of studies was poor, therefore this should be borne in mind when interpreting the model results. CONCLUSIONS: Drug therapy seems to be superior to no drug therapy, no significant differences between the various drugs in terms of efficacy or side effects were found, mainly owing to lack of evidence, and the additional benefits from behavioural therapy (in combination with drug therapy) are uncertain. Given the lack of evidence for any differences in effectiveness between the drugs, the economic model tended to be driven by drug costs, which differed considerably. Future trials examining MPH, DEX and ATX should include the assessment of tolerability and safety as a priority. Longer term follow-up of individuals participating in trials could further inform policy makers and health professionals. Such data could potentially distinguish between these drugs in a clinically useful way. In addition, research examining whether somatic complaints are actually related to drug treatment or to the disorder itself would be informative.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Methods for the Economic Evaluation of Health Care Programmes
Drummond, M. E., Sculpher, M. J., Torrance, G. W., O’Brien, B. J., & Stoddart, G. L. (2005) · doi:10.1093/oso/9780198529446.001.0001 · Cited by 13,648
Self-citationMoher, D., Schulz, K. F., & Altman, D. G. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04337-3 · Cited by 5,373
(1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.12.1073 · Cited by 3,372
Meta-analyses involving cross-over trials: methodological issues
Elbourne, D. R., Altman, D. G., Higgins, J. P., Curtin, F., Worthington, H. V., & Vail, A. (2002) · International Journal of Epidemiology · doi:10.1093/ije/31.1.140 · Cited by 2,305
Biederman, J. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.5.816 · Cited by 1,498
The British Child and Adolescent Mental Health Survey 1999: The Prevalence of DSM-IV Disorders
FORD, T., GOODMAN, R., & MELTZER, H. (2003) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200310000-00011 · Cited by 1,227
SWANSON, J. M., KRAEMER, H. C., HINSHAW, S. P., ARNOLD, L. E., CONNERS, C. K., ABIKOFF, H. B., CLEVENGER, W., DAVIES, M., ELLIOTT, G. R., GREENHILL, L. L., et al. (2001) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200102000-00011 · Cited by 1,157
ADHD Comorbidity Findings From the MTA Study: Comparing Comorbid Subgroups
JENSEN, P. S., HINSHAW, S. P., KRAEMER, H. C., LENORA, N., NEWCORN, J. H., ABIKOFF, H. B., MARCH, J. S., ARNOLD, L. E., CANTWELL, D. P., CONNERS, C. K., et al. (2001) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200102000-00009 · Cited by 974
Wilens, T. E., Faraone, S. V., Biederman, J., & Gunawardene, S. (2003) · Pediatrics · doi:10.1542/peds.111.1.179 · Cited by 872
Michelson, D., Allen, A. J., Busner, J., Casat, C., Dunn, D., Kratochvil, C., Newcorn, J., Sallee, F. R., Sangal, R. B., Saylor, K., et al. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.11.1896 · Cited by 599
JENSEN, P. S., HINSHAW, S. P., SWANSON, J. M., GREENHILL, L. L., CONNERS, C. K., ARNOLD, L. E., ABIKOFF, H. B., ELLIOTT, G., HECHTMAN, L., HOZA, B., et al. (2001) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/00004703-200102000-00008 · Cited by 591
MTA Cooperative Group (2004) · Pediatrics · doi:10.1542/peds.113.4.754 · Cited by 589
Wolraich, M. L., Greenhill, L. L., Pelham, W., Swanson, J., Wilens, T., Palumbo, D., Atkins, M., McBurnett, K., Bukstein, O., August, G., et al. (2001) · Pediatrics · doi:10.1542/peds.108.4.883 · Cited by 502
Kelsey, D. K., Sumner, C. R., Casat, C. D., Coury, D. L., Quintana, H., Saylor, K. E., Sutton, V. K., Gonzales, J., Malcolm, S. K., Schuh, K. J., et al. (2004) · Pediatrics · doi:10.1542/peds.114.1.e1 · Cited by 464
Spencer, T. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950180020004 · Cited by 402
Pelham, W. E., Gnagy, E. M., Burrows-Maclean, L., Williams, A., Fabiano, G. A., Morrisey, S. M., Chronis, A. M., Forehand, G. L., Nguyen, C. A., Hoffman, M. T., et al. (2001) · Pediatrics · doi:10.1542/peds.107.6.e105 · Cited by 378
Spencer, T., Heiligenstein, J. H., Biederman, J., Faries, D. E., Kratochvil, C. J., Conners, C. K., & Potter, W. Z. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1209 · Cited by 333
Methylphenidate and dextroamphetamine treatments of hyperactivity: Are there true nonresponders?
Elia, J., Borcherding, B. G., Rapoport, J. L., & Keysor, C. S. (1991) · Psychiatry Research · doi:10.1016/0165-1781(91)90126-a · Cited by 294
KRATOCHVIL, C. J., HEILIGENSTEIN, J. H., DITTMANN, R., SPENCER, T. J., BIEDERMAN, J., WERNICKE, J., NEWCORN, J. H., CASAT, C., MILTON, D., & MICHELSON, D. (2002) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200207000-00008 · Cited by 292
GREENHILL, L. L., HALPERIN, J. M., & ABIKOFF, H. (1999) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199905000-00011 · Cited by 268
Bupropion versus Methylphenidate in the Treatment of Attention-Deficit Hyperactivity Disorder
BARRICKMAN, L. L., PERRY, P. J., ALLEN, A. J., KUPERMAN, S., ARNDT, S. V., HERRMANN, K. J., & SCHUMACHER, E. (1995) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199505000-00017 · Cited by 254
Swanson, J., Gupta, S., Guinta, D., Flynn, D., Agler, D., Lerner, M., Williams, L., Shoulson, I., & Wigal, S. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70038-x · Cited by 216
Sturm, H., Fernell, E., & Gillberg, C. (2004) · Developmental Medicine & Child Neurology · doi:10.1111/j.1469-8749.2004.tb00503.x · Cited by 186
Placebo-Controlled Evaluation of Ritalin Side Effects
Ahmann, P. A., Waltonen, S. J., Theye, F. W., Olson, K. A., & Van Erem, A. J. (1993) · Pediatrics · doi:10.1542/peds.91.6.1101 · Cited by 178
Newcorn, J. H., Spencer, T. J., Biederman, J., Milton, D. R., & Michelson, D. (2005) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200503000-00008 · Cited by 174
Rubia, K., Noorloos, J., Smith, A., Gunning, B., & Sergeant, J. (2003) · Journal of Abnormal Child Psychology · doi:10.1023/a:1023233630774 · Cited by 170
Pelham, W. E., Sturges, J., Hoza, J., Schmidt, C., Bijlsma, J. J., Milich, R., & Moorer, S. (1987) · PEDIATRICS · doi:10.1542/peds.80.4.491 · Cited by 167
VITIELLO, B., SEVERE, J. B., GREENHILL, L. L., ARNOLD, L. E., ABIKOFF, H. B., BUKSTEIN, O. G., ELLIOTT, G. R., HECHTMAN, L., JENSEN, P. S., HINSHAW, S. P., et al. (2001) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200102000-00013 · Cited by 163
Effects of ethnicity on treatment attendance, stimulant response/dose, and 14-month outcome in ADHD
Arnold, L. E., Elliott, M., Sachs, L., Bird, H., Kraemer, H. C., Wells, K. C., Abikoff, H. B., Comarda, A., Conners, C. K., Elliott, G. R., et al. (2003) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.71.4.713 · Cited by 159
Methylphenidate Dosing: Twice Daily Versus Three Times Daily
Stein, M. A., Blondis, T. A., Schnitzler, E. R., O'Brien, T., Fishkin, J., Blackwell, B., Szumowski, E., & Roizen, N. J. (1996) · Pediatrics · doi:10.1542/peds.98.4.748 · Cited by 151
Weiss, M., Tannock, R., Kratochvil, C., Dunn, D., Velez-Borras, J., Thomason, C., Tamura, R., Kelsey, D., Stevens, L., & Allen, A. J. (2005) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000163280.47221.c9 · Cited by 147
Response to Methylphenidate in Children With ADHD and Comorbid Anxiety
DIAMOND, I. R., TANNOCK, R., & SCHACHAR, R. J. (1999) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199904000-00012 · Cited by 132
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.5.658 · Cited by 129
Cox, D. J., Merkel, R. L., Penberthy, J. K., Kovatchev, B., & Hankin, C. S. (2004) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200403000-00007 · Cited by 120
MATZA, L. S., RENTZ, A. M., SECNIK, K., SWENSEN, A. R., REVICKI, D. A., MICHELSON, D., SPENCER, T., NEWCORN, J. H., & KRATOCHVIL, C. J. (2004) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/00004703-200406000-00005 · Cited by 119
Arnold, L. E. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770280073008 · Cited by 104
Ades, A. E., & Cliffe, S. (2002) · Medical Decision Making · doi:10.1177/027298902400448920 · Cited by 104
Kemner, J. E., Starr, H. L., Ciccone, P. E., Hooper-Wood, C. G., & Crockett, R. S. (2005) · Advances in Therapy · doi:10.1007/bf02849870 · Cited by 99
Double-Blind, Placebo-Controlled Study of Single-Dose Amphetamine Formulations in ADHD
JAMES, R. S., SHARP, W. S., BASTAIN, T. M., LEE, P. P., WALTER, J. M., CZARNOLEWSKI, M., & CASTELLANOS, F. X. (2001) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200111000-00006 · Cited by 92
SOLANTO, M. V., WENDER, E. H., & BARTELL, S. S. (1997) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.1997.7.123 · Cited by 58
Chronis, A. M., Pelham, W. E., Gnagy, E. M., Roberts, J. E., & Aronoff, H. R. (2003) · Journal of Clinical Child & Adolescent Psychology · doi:10.1207/s15374424jccp3201_11 · Cited by 52
Cited by
Systematic reviews: CRD's guidance for undertaking reviews in health care
Tacconelli, E. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70065-7 · Cited by 3,245
Cortese, S., Adamo, N., Del Giovane, C., Mohr-Jensen, C., Hayes, A. J., Carucci, S., Atkinson, L. Z., Tessari, L., Banaschewski, T., Coghill, D., et al. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(18)30269-4 · Cited by 1,402
ADHD in Children and Young People: Prevalence, Care Pathways, and Service Provision
Sayal, K., Prasad, V., Daley, D., Ford, T., & Coghill, D. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30167-0 · Cited by 1,223
Updated European Consensus Statement on diagnosis and treatment of adult ADHD
Kooij, J. J. S., Bijlenga, D., Salerno, L., Jaeschke, R., Bitter, I., Balázs, J., Thome, J., Dom, G., Kasper, S., Nunes Filipe, C., et al. (2019) · European Psychiatry · doi:10.1016/j.eurpsy.2018.11.001 · Cited by 686
Catalá-López, F., Hutton, B., Núñez-Beltrán, A., Page, M. J., Ridao, M., Macías Saint-Gerons, D., Catalá, M. A., Tabarés-Seisdedos, R., & Moher, D. (2017) · PLOS ONE · doi:10.1371/journal.pone.0180355 · Cited by 396
Metadata
- Authors
- King, S., Griffin, S., Hodges, Z., Weatherly, H., Asseburg, C., Richardson, G., Golder, S., Taylor, E., Drummond, M., & Riemsma, R.
- Venue
- Health Technology Assessment
- Published
- 2006-07
- Volume
- 10
- Issue
- 23
- Pages
- iii-iv, xiii
- ISSN
- 1366-5278 (ISSN-L)
- 2046-4924
- OpenAlex
- W2165990772
- Cited by
- 185
- References
- 41
- FWCI
- 2.62
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.